Inactive Instrument

Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Biotechnology & Medical Research

Albireo Pharma, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 05, 2021 at 08:16 am EDT

Albireo Pharma, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 2.428 million compared to USD 1.912 million a year ago. Operating loss was USD 33.032 million compared to USD 18.215 million a year ago. Net loss was USD 36.421 million compared to USD 20.603 million a year ago. Basic loss per share from continuing operations was USD 1.9 compared to USD 1.38 a year ago. For the half year, sales was USD 4.394 million compared to USD 3.461 million a year ago. Operating loss was USD 72.810 million compared to USD 47.765 million a year ago. Net loss was USD 80.154 million compared to USD 52.091 million a year ago. Basic loss per share from continuing operations was USD 4.18 compared to USD 3.58 a year ago.

Latest news about Albireo Pharma, Inc.

French Drugmaker Ipsen Concludes Albireo Pharma Takeover	23-03-02	MT
Albireo Pharma, Inc. Announces Board Changes	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from NASDAQ Composite Index	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P TMI Index	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P Global BMI Index	23-03-02	CI
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Albireo Pharma, Inc. from a group of shareholders.	23-02-28	CI
Ipsen Extends Tender Offer for Albireo Pharma as It Awaits US Antitrust Clearance	23-02-22	MT
Albireo Pharma's Bylvay Granted Priority Review for Rare Genetic Disorder Alagille Syndrome Treatment	23-02-14	MT
Albireo Gets FDA Priority Review of Bylvay in Alagille Syndrome	23-02-14	DJ
Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application	23-02-14	CI
Insider Sell: Albireo Pharma	23-01-20	MT
Guggenheim Downgrades Albireo Pharma to Neutral From Buy	23-01-11	MT
Cowen Downgrades Albireo Pharma to Market Perform From Outperform, Adjusts Price Target to $48 From $68	23-01-11	MT
Jefferies Downgrades Albireo Pharma to Hold From Buy, Adjusts Price Target to $42 From $49	23-01-11	MT
North American Morning Briefing : Stock Futures -2-	23-01-11	DJ
Baird Adjusts Price Target on Albireo Pharma to $45 From $55, Maintains Outperform Rating	23-01-10	MT
HC Wainwright Downgrades Albireo Pharma to Neutral From Buy, Price Target is $42	23-01-10	MT
North American Morning Briefing : More Hawkish Fed -2-	23-01-10	DJ
Top Midday Gainers	23-01-09	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	23-01-09	MT
Transcript : Albireo Pharma, Inc., Ipsen S.A. - M&A Call	23-01-09
Top Premarket Gainers	23-01-09	MT
Wedbush Downgrades Albireo Pharma to Neutral From Outperform After News of Sale to Ipsen, Lowers Price Target to $42 From $53	23-01-09	MT
Albireo Pharma to be Acquired by Ipsen	23-01-09	MT
France's Ipsen Moves to Broaden Rare Disease Portfolio Via $952 Million Purchase of Albireo	23-01-09	MT

Chart Albireo Pharma, Inc.

Duration

Period

More charts

Company Profile

Albireo Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.84B
ARGENX SE	-0.44%	21.48B
BIONTECH SE	-18.35%	20.82B
GENMAB A/S	-7.45%	18.6B
WUXI APPTEC CO., LTD.	-40.31%	16.81B
BEIGENE, LTD.	-26.84%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.4B
SAREPTA THERAPEUTICS, INC.	+20.86%	11.06B

Bio Therapeutic Drugs